Project

Evaluation of p53 aggregation as a drug target in oncology

Duration
01 November 2014 → 31 October 2018
Funding
Regional and community funding: various
Research disciplines
  • Medical and health sciences
    • Morphological sciences
    • Oncology
    • Morphological sciences
    • Oncology
    • Morphological sciences
    • Oncology
Keywords
p53 aggregation
 
Project description

This project includes four major research themes: - Incidence: Using immunofluorescence different tumors will be screened to determine the incidence of protein aggregation. In this way, the application potential aggregation of targeted drugs can be evaluated. In addition, there will be a new test for use are developed on an existing diagnostic platform. This test will be evaluated in selected international multicenter studies. -Causaliteit: Development of new methods to strengthen the relationship between protein aggregation and enhanced cell proliferation. In this way it can be shown that protein aggregation is a good therapetisch target in oncology. Mechanism: Mapping of the physiological causes of protein aggregation. Here there is mainly the physiological stress such as aging, chemotherapy and hypoxia be addressed. The mechanism that the cancer-promoting properties mediates will also be examined. Therapy: To evaluate the therapeutic potential of a number of new ways to prevent protein aggregation. This step includes the search for new therapeutics on the basis of both virtual screening as a screening based on a cellular assay.